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Standfirst 
Routinely collected data from electronic health records (EHRs) could potentially be used to facilitate 
clinical trials. Use of computational phenotypes shows promise for detecting trial-eligible paediatric 
patients; however, moving from EHR identification to recruitment requires consideration of legal, 
ethical and logistical challenges.  
 
Refers to Denburg, M.R. et al. Using electronic health record data to rapidly identify children with 
glomerular disease for clinical research. J. Am. Soc. Nephrol. 30, 2427–2435 (2019). 
 
Commentary   
For paediatric nephrologists, who are used to dealing with rarities, glomerular disorders can be 
considered one of the more ‘common’ manifestations of kidney disease in children and young 
people. Nephrotic syndrome, which affects 2–7 per 100,000 children1, might be one of the first 
nephrological encounters for many paediatricians in training. Glomerular disease also accounts for a 
considerable proportion of long-term kidney injury: 5–14% of all cases of chronic kidney disease and 
15–29% of cases of end-stage renal disease worldwide2. Despite its relative frequency, therapeutic 
advances in paediatric glomerular disease have not been forthcoming, in part because small patient 
numbers limit the achievable statistical power of clinical trials. For example, a sample size of 348 
patients would be needed to detect a minimum 20% difference in the protein:creatinine ratio from a 
mean baseline value of 150mg/mmol in two compared treatment groups. As such, it is of no surprise 
that children are often recruited alongside adults in therapeutic trials, although it is unclear how 
generalizable results are to the paediatric population. One systematic review identified only 27 
paediatric nephrology clinical trials, which accounted for 2.6% of all nephrology studies and 0.9% of 
all studies specifically in paediatric populations3.Clearly, adequately powered clinical trials are 
required to determine the most effective strategies to prevent disease progression in children, not 
least for those with glomerular disease. But how can we identify sufficient numbers of eligible 
participants in an efficient and cost-effective manner?  
 
In the Journal of the American Society of Nephrology, Denburg and colleagues offer a solution to this 
question that has been under our noses for some time: the (almost) ubiquitous electronic health 
record (EHR)4. In their article, Denburg et al. described the derivation of a computational phenotype 
from data elements identified in the medical records and clinical encounters of 231 paediatric 
patients with confirmed glomerular disease. An iterative approach was undertaken to test the rule-
based algorithm using blinded, structured chart reviews in a single tertiary hospital. These findings 
were subsequently validated in another eight specialist. During this period of refinement, the team 
modified the algorithm requirements to account for codes linked to falsely positive cases, such as 
‘acute glomerulonephritis’ and ‘glomerulosclerosis’. The resulting computational phenotype, which 
comprises clinical encounters (that is, three or more nephrology reviews), diagnostic and kidney 
biopsy procedure codes, has a high overall sensitivity (96%), specificity (93%) and negative predictive 
value (97%) for detecting children with glomerular disease. Unfortunately, the data published in the 
paper are not entirely transparent; the total patient numbers used for validation quoted in the 
abstract do not match those given in the tables. Nevertheless, in theory, the use of robust 
computational phenotypes to identify disease-specific  paediatric cohorts could accelerate the 
identification of potential participants for clinical trials.  
 
However, EHRs are designed primarily to record clinical interactions and to audit and improve 
health-care provision, not to recruit clinical trial participants, which has a number of implications. 
First, there is a legal dimension. For example, under the terms of the European General Data 
Protection Regulation, patients identified by the algorithm in this research cannot be directly 
approached by trial investigators without having previously given consent to being contacted 
regarding trial recruitment at some time in the future. Patients must also be offered the opportunity 
to opt out of such data use5. These issues can be circumvented by, for example, implementing alerts 
in EHR systems that first prompt treating clinicians to obtain such consent and subsequently to 
recruit eligible patients when they are next seen.   
 
Second, we must be mindful that for any diagnostic algorithm, the trade-off between sensitivity and 
specificity necessarily results in both false positive and false negative findings. Approaching a patient 
who has been falsely identified as eligible for recruitment could result in increased anxiety for the 
child and their family, additional tests and, in the worst-case scenario, exposure to an unnecessary 
treatment. Moreover, detection of a potentially trial-eligible patient may not automatically equate 
to the patient being fully informed about their condition. Clearly, rigorous checks in close 
collaboration with treating physicians will be required for confirmation of a patient’s eligibility for 
recruitment before patients are approached. 
 
Third, any algorithm can only be used in care settings similar to those in which the algorithm was 
originally developed. For centres using substantially different care pathways and protocols, the 
restriction to three or more clinical encounters might lead to false-negative findings (for example, if 
patients are hospitalized for prolonged periods). Issues around billing and/or funding incentives may 
also lead to particular codes being used more often in some settings than in others. A requirement 
for attending a nephrologist on three or more occasions, as included in this study’s algorithm, may 
mean that populations that do not seek (or do not attend) health-care appointments, which may 
include disadvantaged children, are under-represented in clinical trials. Although children from low-
income families benefit from government-funded health-care initiatives such as Medicaid or the 
Children’s Health Initiative Programme (CHIP), their eligibility criteria and the benefits offered vary 
by jurisdiction, which may also affect the phenotype’s generalizability across regions. 
 
Fourth, even a well-designed and validated digital phenotype is only as good as the data captured 
within the EHR system. For example, if a particular disease type is associated with having a particular 
ethnicity, the false-positive rate might also vary by ethnicity6. Data capture of important 
confounding variables (such as ethnicity or measures of socioeconomic deprivation) and high rates 
of missing data and/or misclassification are ongoing challenges for EHR-based research7. 
 
In summary, Denburg and colleagues have demonstrated that it is possible to use EHRs to identify, 
with a high degree of accuracy, patient populations for whom pragmatic clinical trials are needed. 
Moving on from identification to recruitment requires consideration of several legal, ethical and 
logistical issues; working with patients and their families, health-care professionals, clinical trial 
investigators and data providers is necessary to ensure that the solutions to these issues are 
acceptable to patients, their families and the wider public.  
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